# SonoThera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sonothera

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.sonothera.com
- Total disclosed funding: $156M
- Latest round: Series B (Jun 8, 2026)
- Investors on record: 25

## About

Founded in 2021 and based in California, US, SonoThera, Inc., operates as a biotechnology company that focuses on gene treatment using sonoporation technology. The company was co-founded by Kenneth Greenberg (CEO), and Steve Feinstein (CSO). In June 2026, SonoThera, Inc. raised USD 125.45 million in series B funding co-led by Vida Ventures, Perceptive Advisors, and ARCH Venture Partners, with participation from Ark Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical Co., Ltd., SymBiosis Capital Management, UCB Ventures, Eli Lilly & Company, Bristol-Myers Squibb Company, Vivo Capital, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson Innovation, Medical Excellence Capital, RA Capital Management, F-Prime Capital, Venrock, and Vertex Ventures HC.

SonoThera is a healthcare platform used to deliver payloads through a transient pore in a cell membrane. The company uses sonoporation, a microbubble-mediated biophysical process that provides gene therapy to cure diseases.

The company plans to use June 2026 funding to advance its genetic medicine programs into clinical trials, expand its pipeline, and scale its delivery platform.

## Funding rounds

- Series B, Jun 8, 2026, $125M — ARCH Venture Partners, Venrock, Alexandria Venture Investments, Johnson & Johnson Innovation, Vivo Capital, F-Prime Capital, Otsuka Pharmaceutical Co., Ltd., Eli Lilly & Company, RA Capital Management, Duquesne Family Office, Bristol-Myers Squibb Company, Perceptive Advisors, Illumina Ventures, Vertex Ventures HC, Vida Ventures, UCB Ventures, Leaps by Bayer, CureDuchenne Ventures, Ark Invest, SymBiosis Capital Management, Medical Excellence Capital
- Series A, Apr 29, 2022, $30M — ARCH Venture Partners, Alexandria Venture Investments, Johnson & Johnson Innovation, Wilson Sonsini Goodrich & Rosati, Eli Lilly & Company, Illumina Ventures, Vertex Ventures HC, Foothill Ventures, Formic Ventures, Lifespan Investments, Medical Excellence Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- Wilson Sonsini Goodrich & Rosati — Series A
- Eli Lilly & Company — Series A, Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A, Series B
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series A, Series B
- Foothill Ventures (https://capitalatlas.ai/funds/foothill-ventures) — Series A
- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Series A
- Lifespan Investments — Series A
- Medical Excellence Capital (https://capitalatlas.ai/funds/medical-excellence-capital) — Series A, Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Otsuka Pharmaceutical Co., Ltd. — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Duquesne Family Office — Series B
- Bristol-Myers Squibb Company — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series B
- Ark Invest (https://capitalatlas.ai/funds/ark-invest) — Series B
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series B